[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338919-105":59,"doc-detail-338919-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","targeting-the-dna-damage-response-in-hematological-malignancies","Targeting the DNA damage response in hematological malignancies","","Review summarizing deregulation of the DNA damage response (DDR) and how cancer dependencies on DDR pathways enable therapeutic exploitation through synthetic lethality. Covers progress of DDR inhibitors (DDRi) in hematological cancers, including pre-clinical and clinical evidence supporting DDR inhibition alone or combined with chemotherapeutics and targeted agents. Highlights specific hematological malignancy subtypes showing activity of DDR agents and proposes a framework to guide future clinical trial design.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-the-dna-damage-response-in-hematological-malignancies/338919/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-the-dna-damage-response-in-hematological-malignancies/338919.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What does this review cover about DDR inhibitors in hematological malignancies?","Question",{"text":112,"@type":113},"It summarizes pre-clinical and clinical data on DDR inhibition in hematological malignancies, emphasizing activity of DDR agents as single therapies or combined with chemotherapeutics and targeted agents, and outlines considerations for future clinical trial design.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},338919,1790142025,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":36,"preview_page_count":19,"preview_urls":137},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","TYPE Review  \nPUBLISHED 29 January 2024 DOI 10.3389/fonc.2024.1307839  \nOPEN ACCESS  \nEDITED BY  \nMario I. Vega,  \nUniversity of California, Los Angeles, United States  \nREVIEWED BY Marla Weetall,  \nPTC Therapeutics, United States Francesca Cottini,  \nThe Ohio State University, United States  \n*CORRESPONDENCE Sanjay De Mel  \n [sanjay_widanalage@nuhs.edu.sg](sanjay_widanalage@nuhs.edu.sg)[ ](sanjay_widanalage@nuhs.edu.sg)Anand D. Jeyasekharan  \n [csiadj@nus.edu.sg](csiadj@nus.edu.sg)  \nRECEIVED 05 October 2023  \nACCEPTED 03 January 2024  \nPUBLISHED 29 January 2024  \nCITATION  \nDe Mel S, Lee AR, Tan JHI, Tan RZY, Poon LM, Chan E, Lee J, Chee YL, Lakshminarasappa SR, Jaynes PW and Jeyasekharan AD (2024) Targeting the DNA damage response in hematological malignancies.  \nFront. Oncol. 14:1307839 .  \ndoi: 10.3389/fonc.2024.1307839  \nCOPYRIGHT  \n© 2024 De Mel, Lee, Tan, Tan, Poon, Chan, Lee, Chee, Lakshminarasappa, Jaynes and Jeyasekharan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTargeting the DNA damage response in hematological malignancies  \nSanjay De Mel 1,2,3*, Ainsley Ryan Lee 2, Joelle Hwee Inn Tan 2, Rachel Zi Yi Tan 4, Li Mei Poon 1,3, Esther Chan 1,3, Joanne Lee 1,3, Yen Lin Chee 1,3, Satish R. Lakshminarasappa 5,  \nPatrick William Jaynes 4 and Anand D. Jeyasekharan 1,2,3,4*  \n1 Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore, 2 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 3 NUS Center for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore,  \n4Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore,  \n5 Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore  \nDeregulation of the DNA damage response (DDR) plays a critical role in the pathogenesis and progression of many cancers. The dependency of certain cancers on DDR pathways has enabled exploitation of such through synthetically lethal relationships e.g., Poly ADP-Ribose Polymerase (PARP) inhibitors for BRCAdeﬁcient ovarian cancers. Though lagging behind that of solid cancers, DDR inhibitors (DDRi) are being clinically developed for haematological cancers. Furthermore, a high proliferative index characterize many such cancers, suggesting a rationale for combinatorial strategies targeting DDR and replicative stress. In this review, we summarize pre-clinical and clinical data on DDR inhibition in haematological malignancies and highlight distinct haematological cancer subtypes with activity of DDR agents as single agents orin combination with chemotherapeutics and targeted agents. We aim to provide a framework to guide the design of future clinical trials involving haematological cancers for this important class of drugs.  \nKEYWORDS  \nDNA damage, inhibitors, combination therapy, haematologic malignancies, clinical trials  \nIntroduction  \nDNA damage occurs due to a variety of endogenous or exogenous insults, contributing to genomic instability, a hallmark of cancer (1, 2) . DNA damage response (DDR) pathways have therefore evolved to maintain genomic stability, which is essential for safe and stable transfer of genetic information during cell division (1). Cells have distinct, though partially  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \noverlapping, pathways dedicated for the repair of distinct forms of DNA damage. These include homologous recom","cbCaib9X3XKlSpXJ","https://ap.wps.com/l/cbCaib9X3XKlSpXJ","pdf",991081,16,"English","# Introduction\n## DNA damage and DDR pathways\n## Synthetic lethality and DDR inhibition in hematologic malignancies\n## Scope and structure of the review","[{\"question\":\"What does this review cover about DDR inhibitors in hematological malignancies?\",\"answer\":\"It summarizes pre-clinical and clinical data on DDR inhibition in hematological malignancies, emphasizing activity of DDR agents as single therapies or combined with chemotherapeutics and targeted agents, and outlines considerations for future clinical trial design.\"}]","Targeting the DNA damage response in hematological malignancies | PDF",1790026535,[138,142,146,150],{"page_no":8,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eecf264df07b7bb863899753c008578d.webp",983,1389,{"page_no":14,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f102caf0fbb4905047d6f9001cae09b6.webp",982,1388,{"page_no":81,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38524593a394720a291de5a5152c3c4e.webp",981,1387,{"page_no":19,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afdfe1b99a9c7f4a47bdcebdeb69e757.webp",980,1385]